Target intelligence / Profile preview

NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 (NDUFB6)

Target
NDUFB6
Molecular classification
Enzyme (accessory subunit, not catalytic), Mitochondrial respiratory chain complex I subunit
01

Overview

NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 (NDUFB6) is an accessory, non-catalytic subunit of complex I (NADH:ubiquinone oxidoreductase) in the mitochondrial inner membrane. Although not directly involved in electron transfer catalysis, NDUFB6 is required for the proper assembly and stability of complex I, which initiates the electron transport chain by transferring electrons from NADH to ubiquinone, contributing to the proton gradient used for ATP synthesis. Genetic changes in NDUFB6 are linked to rare mitochondrial diseases, and changes in its expression level have been implicated in metabolic disorders such as type 2 diabetes, insulin resistance, and age-related muscle decline. The molecule is localized to the mitochondrial inner membrane and is essential for efficient aerobic respiration. Although it is not a direct drug target for current therapies, alterations may have biomarker relevance or contribute to mitochondrial dysfunction.

Other names
Complex I-B17CI-B17NADH-ubiquinone oxidoreductase B17 subunitB17 subunitNADH-ubiquinone oxidoreductase beta subunit 617 kDa proteinDD6C4-3DD6C4-4Gm137
02

Mechanism of action

No drugs directly characterized as targeting NDUFB6; NADH interacts as a substrate with the overall complex I; mechanism involves transfer of electrons from NADH to ubiquinone in the mitochondrial electron transport chain

03

Biological functions

Electron transport/Respiratory chainMitochondrial ATP synthesisAerobic respiration
04

Disease associations

Neurodegenerative diseaseMitochondrial diseaseMetabolic disease (e.g., type 2 diabetes and insulin resistance)Other (e.g., leukoencephalopathies)
05

Safety considerations

Disruption may lead to mitochondrial dysfunction; impaired oxidative phosphorylation causing energy deficiency, increased oxidative stress, and multi-organ effects
06

Interacting drugs

NADH (nutraceutical; role as substrate/indirectly related)
07

Biomarkers

Decreased NDUFB6 expression (proposed biomarker for insulin resistance, type 2 diabetes, and aging-related decline in muscle function)

Beyond the preview

Go deeper on NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 (NDUFB6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 (NDUFB6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call